Innovus Pharmaceuticals Inc (NASDAQ:INNV) has been downgraded to Hold in a report by Zacks Investment Research today.
- Updated: October 17, 2016
Zacks Investment Research has downgraded Innovus Pharmaceuticals Inc (NASDAQ:INNV) to Hold in a report released on 10/17/2016.
Previously on Wednesday August 17, 2016, Zacks Investment Research reported on Innovus Pharmaceuticals Inc (NASDAQ:INNV) increased the target price from $0.00 to $0.50 that suggested an upside of 0.09%.
Yesterday Innovus Pharmaceuticals Inc (NASDAQ:INNV) traded -6.47% lower at $0.27. The company’s 50-day moving average is $0.29 and its 200-day moving average is $0.26. The last stock close price is up 4.70% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 538,025 shares of Innovus Pharmaceuticals Inc exchanged hands, down from an avg. volume of 1,285,300
With a total market value of $0, Innovus Pharmaceuticals Inc has with a 52 week low of $0.03 and a 52 week high of $0.66 .
General Information About Innovus Pharmaceuticals Inc (NASDAQ:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.